Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Nabriva Therapeutics plc (NBRV) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 NT 10-Q Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
07/31/2023 8-K Quarterly results
07/24/2023 8-K Quarterly results
07/07/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "SEPARATION AND RELEASE OF CLAIMS AGREEMENT",
"SEPARATION AND RELEASE OF CLAIMS AGREEMENT",
"NABRIVA THERAPEUTICS US, INC. CONSULTING AGREEMENT",
"NABRIVA THERAPEUTICS US, INC. CONSULTING AGREEMENT"
06/01/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
05/15/2023 NT 10-Q Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
04/17/2023 10-K Annual Report for the period ended December 31, 2022
03/31/2023 NT 10-K Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405:
01/20/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "SEPARATION AND RELEASE OF CLAIMS AGREEMENT",
"SEPARATION AND RELEASE OF CLAIMS AGREEMENT",
"NABRIVA THERAPEUTICS US, INC. CONSULTING AGREEMENT",
"NABRIVA THERAPEUTICS US, INC. CONSULTING AGREEMENT"
01/09/2023 8-K Termination of a Material Definitive Agreement, Cost Associated with Exit or Disposal Activities, Other Events, Financial Sta...
Docs: "Nabriva Therapeutics Provides Corporate Update"
11/28/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
11/10/2022 10-Q Quarterly Report for the period ended September 30, 2022
10/04/2022 8-K Other Events  Interactive Data
09/16/2022 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "COMPANIES ACT 2014 A PUBLIC COMPANY LIMITED BY SHARES CONSTITUTION OF NABRIVA THERAPEUTICS PUBLIC LIMITED COMPANY COMPANIES ACT 2014 A PUBLIC COMPANY LIMITED BY SHARES MEMORANDUM OF ASSOCIATION OF NABRIVA THERAPEUTICS PUBLIC LIMITED COMPANY 1. The name of the Company is Nabriva Therapeutics public limited company. 2. The Company is a public limited company for the purposes of Part 17 of the Companies Act 2014. 3. The objects for which the Company is established are: 3.1. To carry on the business of a holding company and to coordinate the administration, finances and activities of any subsidiary companies or associated companies, to do all lawful acts and things whatsoever that are necessary or convenient in carrying on the business of such a holding company and in particular to carry on, i..."
08/17/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
08/03/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/03/2022 8-K Quarterly results
Docs: "® , the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia . Nabriva Therapeutics is also developing CONTEPO™ for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections , including acute pyelonephritis."
07/18/2022 CT ORDER Form CT ORDER - Confidential treatment order:
07/11/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
07/06/2022 8-K Quarterly results
06/29/2022 PRE 14A Form PRE 14A - Other preliminary proxy statements:
05/05/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/05/2022 8-K Quarterly results
03/29/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/29/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "® , the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia . Nabriva Therapeutics is also developing CONTEPO™ for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections , including acute pyelonephritis. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO ® in the United States and certain of its territories."
03/24/2022 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
02/22/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
02/09/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/02/2022 8-K Quarterly results
01/18/2022 8-K Other Events  Interactive Data
01/18/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
01/14/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy